San Francisco, USA and Ingelheim, Germany [7 November 2011] – Boehringer Ingelheim today announced results from a pre-specified interim analysis of a Phase IIb study, named SOUND-C2. These data showed the combination of two oral direct acting anti hepatitis C virus (HCV) compounds (the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with and without ribavirin (RBV), was successful in providing virological response rates at week 12 in treatment-naïve patients infected with the most difficult to treat genotype-1 (GT1) HCV. 1 The shortest treatment duration tested in the study (16 weeks) achieved SVR12 in 59% of patients. None of the five study arms included treatment with interferon. 1,2 These data were presented today at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, USA. 1
Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12...
Data from pre-specified interim analysis of Phase IIb SOUND-C21 trial with Boehringer Ingelheim’s two investigational HCV direct-acting antivirals presented at AASLD - For media outside of the U.S.A. only
Nov 7th, 2011
